---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104015"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:10:07.958624+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immunome Q2 net loss $43.4M; cash $268M; varegacestat Phase 3 topline data by end 2025

## Summary
- Net loss of $43.4M for Q2 2025; cash, equivalents and securities $268M as of June 30.
- R&D expenses $40.5M, G&A $10.0M; cash expected to fund operations into 2027.
- Varegacestat Phase 3 RINGSIDE Part B topline data expected before end of 2025; EMA granted Orphan Drug Designation in July 2025.
- IM-1021 Phase 1 trial dosing at third dose level; IM-3050 IND cleared April 2025, Phase 1 start expected by end 2025.
- Three preclinical ADCs (IM-1617, IM-1340, IM-1335) undergoing IND-enabling work; additional undisclosed ADCs in discovery.

## SEC filing metadata
- accession: 0000950170-25-104015
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/0000950170-25-104015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/imnm-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104015
- JSON: https://secwatch.observer/filing/0000950170-25-104015.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.